This thesis presents a finite element methodology for simulating fluid–solid interactions in the left ventricle (LV) under LVAD support. The developed model was utilised to study the passive and active characteristics of ventricular function in anatomically accurate LV geometries constructed from normal and patient image data. A non–conforming ALE Navier–Stokes/finite–elasticity fluid–solid coupling system formed the core of the numerical scheme, onto which several novel numerical additions were made. These included a fictitious domain (FD) Lagrange multiplier method to capture the interactions between immersed rigid bodies and encasing elastic solids (required for the LVAD cannula), as well as modifications to the Newton–Raphson/line search algorithm (which provided a 2 to 10 fold reduction in simulation time). Additional developments involved methods for extending the model to ventricular simulations. This required the creation of coupling methods, for both fluid and solid problems, to enable the integration of a lumped parameter representation of the systemic and pulmonary circulatory networks; the implementation and tuning of models of passive and active myocardial behaviour; as well as the testing of appropriate element types for coupling non–conforming fluid– solid finite element models under high interface tractions (finding that curvilinear spatial interpolations of the fluid geometry perform best). The behaviour of the resulting numerical scheme was investigated in a series of canonical test problems and found to be convergent and stable. The FD convergence studies also found that discontinuous pressure elements were better at capturing pressure gradients across FD boundaries. The ventricular simulations focused firstly on studying the passive diastolic behaviour of the LV both with and without LVAD support. Substantially different vortical flow features were observed when LVAD outflow was included. Additionally, a study of LVAD cannula lengths, using a particle tracking algorithm to determine recirculation rates of blood within the LV, found that shorter cannulas improved the recirculation of blood from the LV apex. Incorporating myocardial contraction, the model was extended to simulate the full cardiac cycle, converging on a repeating pressure–volume loop over 2 heart beats. Studies on the normal LV geometry found that LVAD implementation restricts the recirculation of early diastolic inflow, and that fluid–solid coupled models introduce greater heterogeneity of myocardial work than was observed in equivalent solid only models. A patient study was undertaken using a myocardial geometry constructed using image data from an LVAD implant recipient. A series of different LVAD flow regimes were tested. It was found that the opening of the aortic valve had a homogenising effect on the spatial variation of work, indicating that the synchronisation of LVAD outflow with the cardiac cycle is more important if the valve remains shut. Additionally, increasing LVAD outflow during systole and decreasing it during diastole led to improved mixing of blood in the ventricular cavity – compared with either the inverse, or holding outflow constant. Validation of these findings has the potential to impact the treatment protocols of LVAD patients.

L’hypertrophie du ventricule gauche (HVG) est un processus adaptif et compensatoire qui se développe conséquemment à l’hypertension artérielle pour s’opposer à l’élévation chronique de la pression artérielle. L’HVG est caractérisée par une hypertrophie des cardiomyocytes suite à l’augmentation de la synthèse d’ADN, une prolifération des fibroblastes, une augmentation du dépôt de collagène et une altération de la matrice extracellulaire (MEC). Ces changements génèrent des troubles de relaxation et mènent au dysfonctionnement diastolique, ce qui diminue la performance cardiaque. La suractivité du système nerveux sympathique (SNS) joue un rôle essentiel dans le développement de l’hypertension artérielle et de l’HVG à cause de la libération excessive des catécholamines et de leurs effets sur la sécrétion des cytokines pro-inflammatoires et sur les différentes voies de signalisation hypertrophiques et prolifératives. Le traitement antihypertenseur avec de la moxonidine, un composé sympatholytique d’action centrale, permet une régression de l’HVG suite à une réduction soutenue de la synthèse d'ADN et d’une stimulation transitoire de la fragmentation de l'ADN qui se produit au début du traitement. En raison de l’interaction entre l’HVG, les cytokines inflammatoires, le SNS et leurs effets sur les protéines de signalisation hypertrophiques, l’objectif de cette étude est de détecter dans un modèle animal d’hypertension artérielle et d’HVG, les différentes voies de signalisation associées à la régression de l’HVG et à la performance cardiaque. Des rats spontanément hypertendus (SHR, 12 semaines) ont reçu de la moxonidine à 0, 100 et 400 µg/kg/h, pour une période de 1 et 4 semaines, via des mini-pompes osmotiques implantées d’une façon sous-cutanée. Après 4 semaines de traitement, la performance cardiaque a été mesurée par écho-doppler. Les rats ont ensuite été euthanasiés, le sang a été recueilli pour mesurer les concentrations des cytokines plasmatiques et les cœurs ont été prélevés pour la détermination histologique du dépôt de collagène et de l'expression des protéines de signalisation dans le ventricule gauche. Le traitement de 4 semaines n’a eu aucun effet sur les paramètres systoliques mais a permis d’améliorer les paramètres diastoliques ainsi que la performance cardiaque globale. Par rapport au véhicule, la moxonidine (400 µg/kg/h) a permis d’augmenter transitoirement la concentration plasmatique de l’IL-1β après une semaine et de réduire la masse ventriculaire gauche. De même, on a observé une diminution du dépôt de collagène et des concentrations plasmatiques des cytokines IL-6 et TNF-α, ainsi qu’une diminution de la phosphorylation de p38 et d’Akt dans le ventricule gauche après 1 et 4 semaines de traitement, et cela avec une réduction de la pression artérielle et de la fréquence cardiaque. Fait intéressant, les effets anti-hypertrophiques, anti-fibrotiques et anti-inflammatoires de la moxonidine ont pu être observés avec la dose sous-hypotensive (100 µg/kg/h). Ces résultats suggèrent des effets cardiovasculaires bénéfiques de la moxonidine associés à une amélioration de la performance cardiaque, une régulation de l'inflammation en diminuant les niveaux plasmatiques des cytokines pro-inflammatoires ainsi qu’en inhibant la MAPK p38 et Akt, et nous permettent de suggérer que, outre l'inhibition du SNS, moxonidine peut agir sur des sites périphériques. / Left ventricular hypertrophy (LVH) is an adaptive and compensatory process that develops in hypertension to oppose the chronic elevation of blood pressure. LVH is characterized by hypertrophy of cardiomyocytes following the increase in DNA synthesis, proliferation of fibroblasts, increased collagen deposition and alteration of the extracellular matrix (ECM). These changes generate relaxation and diastolic dysfunction which reduced cardiac performance. The overactivity of the sympathetic nervous system plays an essential role in the development of hypertension and left ventricular hypertrophy pathogenesis due to the excessive release of catecholamines and norepinephrine spillover and their effects on the secretion of pro-inflammatory cytokines and hypertrophic signaling pathways. Antihypertensive treatment with moxonidine, a centrally acting sympatholytic imidazoline compound, results in prevention of left ventricular hypertrophy, resulting from a sustained reduction of DNA synthesis and transient stimulation of DNA fragmentation that occur early after treatment. Due to the interaction between LVH, inflammatory cytokines, the SNS and their effects on hypertrophic signaling proteins, the objective of this study is to detect in an animal model of hypertension and LVH, the different signaling pathways associated with regression of LVH and cardiac performance. Spontaneously hypertensive rats (SHR, 12 weeks old) received moxonidine at 0, 100 and 400 µg/kg/h, for 1 and 4 weeks, via subcutaneously implanted osmotic minipumps. After 4 weeks of treatment, cardiac performance was measured by echo-Doppler. Then the rats were euthanized, blood was collected for measurement of plasma cytokines and hearts for histologic determination of collagen deposition and for measurement of left ventricular expression of downstream signaling proteins. Treatment for 4 weeks had no effect on systolic parameters but improved diastolic parameters and global cardiac performance. Compared to vehicle, moxonidine (400 µg/kg/h) transiently increased plasma IL-1β after 1 week and reduced left ventricular mass. Similarly, there was a decrease in collagen deposition and plasma concentrations of IL-6 and TNF-α, and decreased phosphorylation of p38 and Akt in the left ventricle after 1 and 4 weeks treatment, in association with reduced blood pressure and heart rate. Interestingly, the anti-hypertrophic, anti-fibrotic, and anti-inflammatory effects of moxonidine were observed with a sub-hypotensive dose (100µg/kg/h). These results suggest the beneficial cardiovascular effects of moxonidine associated with improved cardiac performance, regulation of inflammation by decreasing pro-inflammatory plasma levels, inhibition of p38 MAPK and Akt, and allow us to suggest that besides inhibiting the SNS, moxonidine may act on peripheral sites.

La moxonidine, un médicament antihypertenseur sympatholytique de type imidazolinique, agit au niveau de la médulla du tronc cérébral pour diminuer la pression artérielle, suite à l’activation sélective du récepteur aux imidazolines I1 (récepteur I1, aussi nommé nischarine). Traitement avec de la moxonidine prévient le développement de l’hypertrophie du ventricule gauche chez des rats hypertendus (SHR), associé à une diminution de la synthèse et une élévation transitoire de la fragmentation d’ADN, des effets antiprolifératifs et apoptotiques. Ces effets se présentent probablement chez les fibroblastes, car l’apoptose des cardiomyocytes pourrait détériorer la fonction cardiaque. Ces effets apparaissent aussi avec des doses non hypotensives de moxonidine, suggérant l’existence d’effets cardiaques directes. Le récepteur I1 se trouvé aussi dans les tissus cardiaques; son activation ex vivo par la moxonidine stimule la libération de l’ANP, ce qui montre que les récepteurs I1 cardiaques sont fonctionnels malgré l’absence de stimulation centrale. Sur la base de ces informations, en plus du i) rôle des peptides natriurétiques comme inhibiteurs de l’apoptose cardiaque et ii) des études qui lient le récepteur I1 avec la maintenance de la matrix extracellulaire, on propose que, à part les effets sympatholytiques centrales, les récepteurs I1 cardiaques peuvent contrôler la croissance-mort cellulaire. L’activation du récepteur I1 peut retarder la progression des cardiopathies vers la défaillance cardiaque, en inhibant des signaux mal adaptatifs de prolifération et apoptose. Des études ont été effectuées pour : 1. Explorer les effets in vivo sur la structure et la fonction cardiaque suite au traitement avec moxonidine chez le SHR et le hamster cardiomyopathique. 2. Définir les voies de signalisation impliquées dans les changements secondaires au traitement avec moxonidine, spécifiquement sur les marqueurs inflammatoires et les voies de signalisation régulant la croissance et la survie cellulaire (MAPK et Akt). 3. Explorer les effets in vitro de la surexpression et l’activation du récepteur I1 sur la survie cellulaire dans des cellules HEK293. 4. Rechercher la localisation, régulation et implication dans la croissance-mort cellulaire du récepteur I1 in vitro (cardiomyocytes et fibroblastes), en réponse aux stimuli associés au remodelage cardiaque : norépinephrine, cytokines (IL-1β, TNF-α) et oxydants (H2O2). Nos études démontrent que la moxonidine, en doses hypotensives et non-hypotensives, améliore la structure et la performance cardiaque chez le SHR par des mécanismes impliquant l’inhibition des cytokines et des voies de signalisation p38 MAPK et Akt. Chez le hamster cardiomyopathique, la moxonidine améliore la fonction cardiaque, module la réponse inflammatoire/anti-inflammatoire et atténue la mort cellulaire et la fibrose cardiaque. Les cellules HEK293 surexprimant la nischarine survivent et prolifèrent plus en réponse à la moxonidine; cet effet est associé à l’inhibition des voies ERK, JNK et p38 MAPK. La surexpression de la nischarine protège aussi de la mort cellulaire induite par le TNF-α, l’IL-1β et le H2O2. En outre, le récepteur I1 s’exprime dans les cardiomyocytes et fibroblastes, son activation inhibe la mort des cardiomyocytes et la prolifération des fibroblastes induite par la norépinephrine, par des effets différentiels sur les MAPK et l’Akt. Dans des conditions inflammatoires, la moxonidine/récepteur aux imidazolines I1 protège les cardiomyocytes et facilite l’élimination des myofibroblastes par des effets contraires sur JNK, p38 MAPK et iNOS. Ces études démontrent le potentiel du récepteur I1/nischarine comme cible anti-hypertrophique et anti-fibrose à niveau cardiaque. L’identification des mécanismes cardioprotecteurs de la nischarine peut amener au développement des traitements basés sur la surexpression de la nischarine chez des patients avec hypertrophie ventriculaire. Finalement, même si l’effet antihypertenseur des agonistes du récepteur I1 centraux est salutaire, le développement de nouveaux agonistes cardiosélectifs du récepteur I1 pourrait donner des bénéfices additionnels chez des patients non hypertendus. / Moxonidine, an antihypertensive sympatholytic imidazoline compound, reduces blood pressure by selective activation of non-adrenergic imidazoline I1-receptors (also known as nischarin) in brainstem medulla. Moxonidine prevents left ventricular hypertrophy development in hypertensive rats, associated with reduced cardiac DNA synthesis and early transient increase in DNA fragmentation. It is likely that the anti-proliferative and apoptotic effects occur in fibroblasts, as cardiomyocyte apoptosis may deteriorate cardiac function. The effects also occurred to sub-hypotensive doses, suggesting a blood-pressure-independent mechanism and pointing to a local cardiac action. Imidazoline I1-receptors have been identified in cardiac tissues, and their ex vivo activation by moxonidine stimulates ANP release, demonstrating that cardiac imidazoline I1-receptors are functional without the contribution of the central nervous system. Based on the above studies and on i) the role of natriuretic peptides in inhibition of myocardial cell apoptosis and ii) studies linking imidazoline I1-receptors to the maintenance of the extracellular matrix and PC12 cell survival, we propose that apart from centrally-mediated sympatholytic function, imidazoline I1-receptors in the heart may control cell growth and death. Activation of imidazoline receptors may delay the progression of cardiac pathologies into heart failure by inhibition of maladaptive proliferative signalling and downstream apoptotic pathways. In order to test this hypothesis studies were performed to: 1. Explore the in vivo effects of moxonidine on cardiac structure and function in SHR and cardiomyopathic hamsters. 2. Define the pathways involved in the observed changes following moxonidine treatment, specifically, on inflammatory markers and pathways involved in LVH and cardiac cell survival/death (MAPK and Akt). 3. Explore in vitro the effect of imidazoline I1-receptor activation by moxonidine, on cell survival by over-expressing nischarin in HEK293 cells, to circumvent the lack of specific imidazoline I1-receptor agonists and antagonists. 4. Investigate in vitro, imidazoline I1-receptor localization (cardiomyocytes and fibroblasts), regulation and implication in cell growth/death in response to cardiac remodelling-associated stimuli: norepinephrine, cytokines (IL-1β, TNF-α), and oxidants (H2O2). The studies reveal that hypotensive and sub-hypotensive concentrations of moxonidine improve cardiac structure and performance in SHR by mechanisms that involve inhibition of cytokines, p38MAPK, and Akt signalling pathways. In cardiomyopathic hamsters moxonidine improves cardiac performance, in association with differential inflammatory/anti-inflammatory responses that culminate in attenuated cardiomyocyte death and fibrosis and altered collagen type expression. HEK293 cells, transfected with nischarin cDNA, show increased viability/proliferation in response to moxonidine. The overall survival response is associated with moxonidine’s inhibition of ERK, JNK, and p38MAPK. Nischarin also opposes the reduced cell viability in response to oxidative stimuli (TNF-α, IL-1β and H2O2), with differential responses to moxonidine. Furthermore, the imidazoline I1-receptor is expressed in cardiac fibroblasts and myocytes and its activation inhibits norepinephrine-induced cardiomyocyte death and fibroblast proliferation, through differential effects on MAPKs and Akt. Moxonidine/imidazoline I1-receptor protects cardiomyocytes and facilitates elimination of myofibroblasts in inflammatory conditions, through opposite effects on JNK, p38MAPK and iNOS activity. These studies emphasize the potential importance of imidazoline I1-receptor/nischarin as an anti-hypertrophic and anti-fibrotic target. Identification of the cardio-protective mechanisms of cardiac nischarin could result in specifically-tailored cell/gene-driven nischarin treatments, which could be important for patients with heart disease. Also, while the antihypertensive action of centrally acting compounds is appreciated, new cardiac-selective I1-receptor agonists may confer additional benefit.

La fraction d’éjection du ventricule gauche est un excellent marqueur de la fonction cardiaque. Plusieurs techniques invasives ou non sont utilisées pour son calcul : l’angiographie, l’échocardiographie, la résonnance magnétique nucléaire cardiaque, le scanner cardiaque, la ventriculographie radioisotopique et l’étude de perfusion myocardique en médecine nucléaire. Plus de 40 ans de publications scientifiques encensent la ventriculographie radioisotopique pour sa rapidité d’exécution, sa disponibilité, son faible coût et sa reproductibilité intra-observateur et inter-observateur. La fraction d’éjection du ventricule gauche a été calculée chez 47 patients à deux reprises, par deux technologues, sur deux acquisitions distinctes selon trois méthodes : manuelle, automatique et semi-automatique. Les méthodes automatique et semi-automatique montrent dans l’ensemble une meilleure reproductibilité, une plus petite erreur standard de mesure et une plus petite différence minimale détectable. La méthode manuelle quant à elle fournit un résultat systématiquement et significativement inférieur aux deux autres méthodes. C’est la seule technique qui a montré une différence significative lors de l’analyse intra-observateur. Son erreur standard de mesure est de 40 à 50 % plus importante qu’avec les autres techniques, tout comme l’est sa différence minimale détectable. Bien que les trois méthodes soient d’excellentes techniques reproductibles pour l’évaluation de la fraction d’éjection du ventricule gauche, les estimations de la fiabilité des méthodes automatique et semi-automatique sont supérieures à celles de la méthode manuelle. / Left ventricular ejection fraction is an excellent indicator of cardiac function. Many invasive and non-invasive techniques can be used for its assessment: angiography, echocardiography, cardiac MRI, computed tomography of the heart, multigated radionuclide angiography and myocardial perfusion imaging. More than 40 years of scientific publication praise the multigated radionuclide angiography for its execution speed, its availability, its low cost and intrarater and interrater reproducibility. The left ventricular ejection fraction was calculated twice for 47 patients, using two raw data acquisitions, two technologists and three software platforms: one fully manual, one semi-automatic and one fully automatic. In general, the automatic and semi-automatic methods showed greater reproducibility, a smaller standard error of measurement and minimal detectable change than the manual method, whereas the manual method systematically gave a significantly lower quality of result. It was the only technique that showed significant intrarater difference, and its standard error of measurement and minimal detectable change were 40% to 50% higher than those of automatic and semi-automatic methods. Even though all three techniques are all excellent and reliable options, reliability coefficient estimations were superior using automatic and semi-automatic methods as compared to the manual method.

The thesis discusses the education of patients with left ventricular support HeartMate II. Theoretical part is focused on education and its ethical and legal aspects, on the description of the educational process. Furthermore it focuses on heart supports, especially on left ventricular assist device HeartMate II. To provide a comprehensive overview, I have included also information about the anatomy and physiology of the cardiovascular system and the section on heart failure. I described the specifics of nursing care for patients with implanted HeartMate II system and the educational topics that should be part of the education of these patients. The empirical part was prepared as a quantitative research, where research sample was 47 respondents. Respondents consisted of nurses who educate patients after implantation of the HeartMate II at the cardiovascular surgical intensive care unit. To create the feedback I complemented a quantitative research with structured interviews with patients after implantation of the HeartMate II. The aim of the research was to determine the status and range of education of patients with left ventricular assist device HeartMate II. This thesis further maps the topics on which is placed the emphasis in education and vice versa topics that would need to focus more on....

Introdução: Nos pacientes coronarianos, portadores de disfunção ventricular esquerda (DVE), a mortalidade cirúrgica da revascularização miocárdica é 3 a 4 vezes maior do que a encontrada em pacientes com função ventricular normal, sendo fundamental a seleção daqueles que efetivamente poderão ser beneficiados pela cirurgia. As metanálises indicam que a pesquisa da viabilidade miocárdica é útil nesta seleção, impactando em melhora da contratilidade ventricular e redução de mortalidade quando a revascularização é realizada em pacientes com ventrículo esquerdo viável; entretanto, os estudos clínicos randomizados não encontraram os mesmos resultados. Isso porque, apesar de 50% desses pacientes apresentarem quantidades substanciais de viabilidade miocárdica, nem todos conseguem melhorar a contratilidade ventricular esquerda após a revascularização, devido à existência de outros fatores que interferem nessa melhora. Objetivos: Determinar os fatores preditores de melhora da contratilidade ventricular esquerda em pacientes com fração de ejeção < 50% submetidos à cirurgia de revascularização miocárdica (CRM) isolada e o tempo necessário para a ocorrência dessa melhora contrátil. Métodos: Estudo prospectivo observacional que avaliou pacientes coronarianos com DVE submetidos a eletrocardiograma e ecocardiograma no pré-operatório e 1, 3, 6, 9 e 12 meses após a CRM, e à ressonância magnética cardíaca (RMC) com estresse farmacológico com dipiridamol e realce tardio com gadolínio no pré-operatório e após 3 e 12 meses da revascularização, buscando associações entre a melhora da contratilidade ventricular esquerda e as diversas variáveis dos pacientes. Resultados: Foram estudados 306 segmentos miocárdicos de 18 pacientes, com idade de 59,5 + 7,4 anos. Ocorreu melhora contrátil em 47 (29%) segmentos do ventrículo esquerdo que apresentavam alterações contráteis pré-operatórias (p < 0,0001). A análise multivariada identificou três fatores preditores de melhora da contratilidade ventricular esquerda: a ausência de onda Q patológica, que aumenta em 172% a chance de melhora, a presença de viabilidade miocárdica, que aumenta em 282% a chance de melhora e a ausência de isquemia miocárdica, que aumenta em 392% a chance de melhora (razão de chances 2,72, IC 95%, 1,24 a 5,92, p = 0,012; razão de chances 3,82, IC 95%, 1,79 a 8,16, p = 0,0005; e razão de chances 4,92, IC 95%, 2,13 a 11,36, p = 0,0002, respectivamente). Em 9 (75%) pacientes a melhora da contratilidade ventricular ocorreu nos 3 primeiros meses após a CRM e em 3 (25%) pacientes ocorreu nos 9 meses seguintes Conclusões: Os três fatores preditores de melhora da contratilidade ventricular esquerda encontrados foram a ausência de onda Q patológica no eletrocardiograma, e a presença de viabilidade e ausência de isquemia miocárdicas na RMC. A recuperação da contratilidade ventricular esquerda ocorreu predominantemente nos 3 primeiros meses após a CRM, no entanto foi verificada uma melhora progressiva até o final dos 12 meses de seguimento. / Introduction: In patients with coronary artery disease (CAD) and left ventricular dysfunction, the surgical mortality from coronary artery bypass graft (CABG) is 3 to 4 times higher than that reported for patients with normal ventricular function, and selecting those who can effectively benefit from the surgery is essential. Meta-analyses have indicate that myocardial viability assessment is useful in this selection, impacting on left ventricular contractility improvement and mortality reduction when revascularization is performed in patients with viable left ventricles; However, randomized clinical trials have not found the same results. Although 50% of these patients have substantial myocardial viability, not all of them can improve left ventricular contractility after revascularization, due to other factors that interfere with this improvement. Objectives: This study aims to determine the predictors of improvement in left ventricular contractility in patients with an ejection fraction of <50% who underwent isolated CABG, as well as the time required for this improvement in contractility. Methods: This prospective observational study assessed patients with CAD and left ventricular dysfunction who underwent electrocardiography and echocardiography during the preoperative period and 1, 3, 6, 9, and 12 months after CABG and cardiac magnetic resonance with pharmacological stress with dipyridamole and late gadolinium enhancement in the preoperative period and 3 and 12 months after revascularization, to determine the associations between the evolution of left ventricular contractility and several patient-related variables. Results: A total of 306 myocardial segments of the 18 patients, aged 59.5 ± 7.4 years, were studied. There was a contractile improvement in 47 (29%) segments of the left ventricle that presented preoperative contractile abnormalities (p < 0.0001). The multivariate analysis identified three predictors of left ventricular contractility improvement: the absence of pathological Q waves, which increases the chance of improvement by 172% (odds ratio (OR) 2.72, 95% confidence interval (CI), 1.24-5.92, p = 0.012), the presence of myocardial viability, which increases the chance of improvement by 282% (OR 3.82, 95% CI, 1.79-8.16, p = 0.0005), and the absence of myocardial ischemia, which increases the chances of improvement by 392%, (OR 4.92, 95% CI, 2.13-11.36, p = 0.0002). In 9 (75%) patients the improvement in ventricular contractility occurred in the first 3 months after CABG, and in 3 (25%) patients, it occurred in the following 9 months. Conclusions: The three predictors of left ventricular contractility improvement were the absence of pathological Q waves on an electrocardiogram, the presence of myocardial viability and the absence of signs of ischemia on cardiac MRI. The improvement in left ventricular contractility occurred predominantly in the first three months after CABG, but a progressive recovery was observed until the end of the 12-month follow-up period.

Os barorreceptores regulam as variações da pressão arterial (PA) momento-amomento e respondem pela modulação adequada do sistema nervoso autônomo em situações fisiológicas. Na hipertensão arterial há comprometimento da função autonômica, com diminuição da sensibilidade do barorreflexo e predomínio da atividade simpática, além de alterações morfofuncionais cardíacas progressivas. O treinamento físico (TF), por sua vez, é uma abordagem eficaz em melhorar essas disfunções. Por ter importância clínica em diversas situações patológicas, neste trabalho, testamos a hipótese de que o barorreflexo seria um mecanismo determinante para as adaptações cardiovasculares e autonômicas à hipertensão e ao treinamento físico. Para tanto, verificamos o impacto da remoção dos barorreceptores arteriais, pelo método da desnervação sino-aórtica, nas adaptações da PA, freqüência cardíaca (FC), modulação autonômica, função e morfometria cardíacas induzidas pelo TF na hipertensão e na normotensão em animais. Ratos espontaneamente hipertensos e normotensos Wystar foram submetidos ou não à desnervação sino-aórtica e divididos em treinados e sedentários. O TF foi realizado em esteira (5x/semana, 60 minutos, intensidade de 50-60% da velocidade máximo do teste de esforço). Após 10 semanas, artéria e veia femorais foram canuladas para registro direto da PA e avaliação da sensibilidade barorreflexa através da infusão de drogas vasoativas. Funções sistólica (frações de ejeção e de encurtamento), diastólica (tempo de relaxamento isovolumétrico e razão das ondas E e A) e morfometria do ventrículo esquerdo (diâmetro e espessura relativa da parede) foram avaliadas por ecocardiografia. A fibrose cardíaca foi quantificada pela avaliação histológica (coloração com picro sirius para visualização de colágeno). A variabilidade da FC (VFC) e da PA (VPA) foram analisadas nos domínios do tempo e da freqüência (método FFT). A desnervação sino-aórtica provocou um déficit exacerbado no baroreflexo, grande aumento da VPA e redução da VFC dos ratos submetidos a este procedimento, sem alterar a PA e a FC basais. O TF nos grupos não-desnervados provocou bradicardia de repouso e redução da PA média apenas no grupo hipertenso (-16%), o qual também normalizou a sensibilidade barorreflexa. O TF induziu diminuição marcante da modulação simpática cardiovascular nos ratos hipertensos (-53%), além de aumento da modulação vagal cardíaca em normotensos (+8%) e hipertensos (+13%). Em contrapartida, os grupos treinados desnervados, tanto normotensos quanto hipertensos, não apresentaram tais benefícios hemodinâmicos e autonômicos ao TF, havendo, inclusive, aumento da PA média (5%) e FC (10%) no grupo normotenso desnervado. Embora a função sistólica tenha permanecido preservada nos animais desnervados, a função diastólica mostrou-se pior nestes grupos e aumentou em 2x o volume de colágeno ventricular. Nos hipertensos, a desnervação sino-aórtica acentuou não só a disfunção diastólica, mas também o grau de hipertrofia (+20%) e fibrose do ventrículo esquerdo (+64%). Com o TF, houve importante melhora da função diastólica nos animais hipertensos com barorreflexo intacto. O TF também foi eficaz em atenuar a hipertrofia cardíaca concêntrica da hipertensão, tanto nos animais intactos quanto nos desnervados, além de diminuir a fibrose cardíaca. Desta forma, estes achados demonstram que o barorreflexo pode intermediar as adaptações cardiovasculares e autonômicas induzidas pela hipertensão arterial, além de ser um mecanismo fundamental para tais ajustes decorrentes do treinamento físico, tanto em normotensos quanto em hipertensos. / Baroreceptors regulate moment-to-moment changes in blood pressure (BP) and respond for the adequate modulation of autonomic nervous system in physiological situations. In arterial hypertension, there is autonomic function impairment with descreased baroreflex sensitivity and sympathetic activity predominance, besides the progressive cardiac morphofunctional alterations. Exercise training (ET) is an effective approach to improve these dysfunctions. Because baroreflex has clinical relevance in several pathological conditions, in this study, we hypothesized that baroreflex would be a key mechanism for cardiovascular and autonomic adaptations to hypertension and exercise training. For these purposes, it was verified the impact of arterial baroreceptors removal, by sinoaortic denervation method, in BP, heart rate, autonomic modulation, structural and functional cardiac adaptations induced by the ET in hypertensive and normotensive animals. Spontaneously hypertensive rats and Wystar normotensive rats underwent sinoaortic denervation or sham surgery. Afterwards, they were divided in sedentary or trained groups. ET was performed on a treadmill (5x/week, 60 min, intensity 50-70 of maximal speed of exercise test). After a 10-week follow up, femoral artery and vein were cannulated to direct BP record and to evaluate baroreflex sensitivity by vasoactive drugs infusion. Left ventricle systolic (ejection and shortening fractions) and diastolic (isovolumetric relaxation time and E/A ratio) functions and morphometry (diameter and relative wall thickness) were evaluated by echocardiography. Cardiac fibrosis was quantified by histological analysis (picro sirius stained tissue for collagen visualization). BP and HR variabilities were analyzed in time and frequency domains by the FFT method. Sinoaortic denervation caused a striking baroreflex deficit in rats that underwent this procedure without altering baseline mean BP and HR. Nevertheless, sinoaortic denervation sharply increased BP variability and decreased HR variability. ET in non-denervated groups induced resting bradycardia and mean BP reduction only in hypertensive rats (-16%), which were also favored by baroreflex sensitivity normalization. ET caused an important decrease in sympathetic modulation in hypertensives (-53%) and increased vagal modulation in both, normotensive (+8%) and hypertensive (+13%) groups. Inversely, denervated-trained groups did not show hemodynamic and autonomic adaptive benefits to ET. Indeed, it was found augmented HR (+10%) and mean BP (+5%) in denervated-trained normotensive group. Although systolic function was preserved in denervated animals, diastolic function was impaired in these groups and left ventricle collagen volume fraction was 2-fold increased in normotensives. In hypertensives, sinoaortic denervation not only enhanced diastolic dysfunction, but also the cardiac hypertrophy index (+20%) and fibrosis (+64%). ET improved diastolic function in hypertensive rats with intact baroreflex. ET was also effective in attenuating hypertensive concentric cardiac hypertrophy in both, intact and denervated animals, besides reducing left ventricular fibrosis. In conclusion, baroreflex seems to mediate cardiovascular and autonomic adaptations to hypertension and is a crucial mechanism for these adaptations to ET either in normotensive and hypertensive rats.

Le remodelage ventriculaire est un processus réactionnel pouvant faire suite à un infarctus du myocarde (IDM), évènement ischémique aigu survenant lors de l'obstruction d'une artère coronaire. Le remodelage provoque alors des changements géométriques et fonctionnels du tissu myocardique qui permettent de maintenir et d'adapter la fonction cardiaque. Lorsque ce processus est délétère, la maladie évolue vers l'insuffisance cardiaque, ce qui altère le pronostic et la qualité de vie des patients. L'adénosine est un nucléoside ubiquitaire dont les effets sur le remodelage ventriculaire après IDM sont encore peu connus et dépendent du type de récepteur activé. Au sein de notre laboratoire, de précédentes études in vitro ont montré que l'adénosine régule de nombreux acteurs clés du remodelage. Dans ce travail de thèse, nous avons émis l'hypothèse que l'adénosine pouvait avoir un effet bénéfique sur le remodelage ventriculaire après la survenue d'un IDM. Dans un premier temps, nous avons montré que la tomographie par émission de positrons (TEP) permet de caractériser précisément les séquelles d'IDM et de prédire le remodelage ventriculaire chez le rat après occlusion coronaire. Cette technique nous a permis de mettre en évidence le cas d'un rat ayant survécu à un IDM touchant plus de 70% de son ventricule gauche. Dans un deuxième temps, nous avons montré que l'administration chronique d'adénosine, à long terme après IDM chez le rat, permet de maintenir la contractilité cardiaque dans la zone bordant l'IDM. Cet effet cardioprotecteur peut s'expliquer par une stimulation de l'angiogenèse elle-même due à un recrutement de cellules endothéliales progénitrices circulantes. Ensuite, nous avons montré que la chimiokine Monocyte Chemotactic Protein 3 est capable de stimuler la migration des cellules endothéliales progénitrices et est ainsi un agent thérapeutique potentiel après IDM. Enfin, nous avons commencé l'étude préclinique d'une molécule agoniste du récepteur A2A à l'adénosine et antagoniste du récepteur A3, un candidat particulièrement prometteur pour prévenir le remodelage ventriculaire après IDM / Left ventricular (LV) remodeling can follow myocardial infarction (MI), an acute ischemic event which occurs after occlusion of a coronary artery. Remodeling allows maintaining and adapting cardiac function by geometric and functional changes of the myocardium. If this process becomes maladaptive, the patients? prognostic and life quality are impaired by the development of heart failure. Adenosine is an ubiquitous nucleoside with partially characterized effects on LV remodeling. These effects depend on the type of receptor activated. Previous in vitro studies from our laboratory have shown that adenosine regulates several key processes involved in LV remodeling. Here, we hypothesized that adenosine may have beneficial effects on LV remodeling after MI. First, we showed that positon emission tomography (PET) can accurately characterize MI severity and predicts subsequent LV remodeling in the rat model of MI induced by coronary occlusion. Using this technique, we described the case of a rat that survived after a massive infarct covering 70% of the left ventricle. Second, we showed that a chronic administration of adenosine preserves cardiac contractility in the border zone, two months after MI. This cardioprotective effect can be explained, in part, by the stimulation of angiogenesis involving a stimulation of the recruitment of endothelial progenitor cells to the heart. Then, we showed that the Monocyte Chemotactic Protein 3 stimulates the migration of endothelial progenitor cells and is thereby a potential therapeutic target after MI. Finally, we started the preclinical study of an A2A agonist / A3 antagonist, a promising candidate to prevent LV remodeling after MI

Hintergrund: Elastischer Ohrknorpel ist eine potentielle Quelle fuer autologe Zellen um die luminalen Oberflaechen von links ventrikularen assist systemen (LVAD''s) zu besiedeln zu dem Zweck die Biokompatibilitaet dieser Systeme zu verbessern. Wir prueften dieses Potential der Ohrknorpelzellen in vitro und in vivo in einem Tiermodel (Kalb). Methoden: In vitro, Elastischer Knorpel wurde von dem Ohr eines Kalbes unter Lokalanaesthesie gewonnen, isoliert, und in Gewebekultur gezuechtet. Chondrocytes wurden immunocytochemisch analysiert, transferriert in Zellkulturmedium, zweimal umgesetzt, und auf die blutkontaktierenden, luminalen Oberflaechen von vier LVAD''s (HeartMate(R); Thermo Cardiosystems, Inc., Woburn, MA) gesiedelt. Die beschichteten Zelloberflaechen wurden preconditioniert unter Flussbedingungen in vitro, um die Zellhaftung an den luminalen Oberflaechen der LVAD''s zu beguenstigen. Die Effiezienz der Zellbesiedelung und der kumulative Zellverlust unter Flussbedingungen in vitro wurden quantifiziert. In vivo, eine der vier chondrocyte-beschichteten und preconditionierten LVAD''s wurde in das Kalb implantiert, welches urspruenglich Ohrknorpelspender diente. Das LVAD wurde fuer sieben Tage betrieben, dann explantiert und pathologisch und histologisch evaluiert unter der Benutzung eines Scanningelektronenmikroskopes und eines Transmissionelektronenmikroskopes. Resultate: Die luminalen Oberflaechen von vier LVAD''s wurden mit autologen Ohrknorpelzellen besiedelt. Die Effiezienz der Zellbesiedelung betrug 95.11± 4.23% (n = 4). Der kumulative Zellverlust unter Flussbedingungen in vitro war geringer als 12% (n = 4). Nach sieben Tagen der in vivo Implantation zeigten die luminalen Oberflaechen des implantierten LVAD eine intakte, fest haftende Zellbesiedelung. Es wurden keine Thromboembolien waehrend der Nekropsie festgestellt. Schlussfolgerungen: Ohrknorpel stellt eine einfach und schnell erreichbare Quelle fuer autologe Ohrknorpelzellen dar, dessen Collagen Typ II und andere wichtige Bestandteile der extrazellulaeren Matrix sie dazu befaehigt, fest an den luminalen Oberflaechen der LVAD''s zu haften. Die hier beschriebene einfache Methode der Knorpelgewinnung und der Zellisolierung kann benutzt werden, um eine autologe Zellbeschichtung von LVAD''s und anderen implantierbaren kardiovaskulaeren Systemen vorzunehmen mit dem Ziel die Biokompatibilitaet dieser zu verbessern. Unsere erfolgreiche Feasibilitystudie in einem Kalbmodel fordert weitere in vivo Studien. / Background: Auricular elastic cartilage is a potential source of autologous cells for lining the luminal surfaces of left ventricular assist devices (LVAD''s) to improve long-term biocompatibility. We evaluated this potential in vitro and in vivo in a calf model. Methods: In vitro, auricular cartilage was harvested from the anesthetized ear of a calf, isolated, and cultured on tissue culture dishes. Primary chondrocytes were typed by immunocytochemistry, transferred into culture media, passaged twice, and seeded onto the blood-contacting luminal surfaces of four LVAD''s (HeartMate(R); Thermo Cardiosystems, Inc., Woburn, MA). The seeded cell linings were preconditioned under flow conditions in vitro to promote cell adhesion to the luminal surfaces. Seeding efficiency and cumulative cell loss under flow conditions in vitro were quantitated. In vivo, one of the four preconditioned, autologous chondrocyte-lined LVAD''s was implanted into the tissue-donor calf; run for 7 days; explanted; and finally evaluated grossly, by scanning electron microscopy, and by transmission electron microscopy. Results: Autologous chondrocytes were seeded onto the luminal surfaces of the four LVAD''s. The seeding efficiency was 95.11± 4.23% (n = 4). Cumulative cell loss during preconditioning under flow conditions in vitro did not exceed 12% (n = 4). After 7 days of in vivo implantation, the luminal surfaces of the implanted LVAD demonstrated an intact, strongly adherent cellular lining. There was no evidence of thromboembolic events at necropsy. Conclusions: Auricular elastic cartilage is a ready and easily accessible source of chondrocytes whose ability to produce collagen II and other important extracellular matrix constituents allows them to adhere strongly to the luminal surfaces of LVAD''s. The simple method of isolating and expanding auricular chondrocytes presented here could be used to provide autologous cell linings for LVAD''s and other cardiovascular devices to improve their long-term biocompatibility. Our successful short-term feasibility study in a calf model warrants further study in vivo.

A doença cardiovascular (DCV) é a principal causa de mortalidade nos pacientes com doença renal crônica (DRC) e a hipertrofia de ventrículo esquerdo (HVE), a alteração mais freqüente. A remodelação cardíaca (RC) patológica ocorre em resposta a agressões como sobrecarga de volume ou de pressão e é influenciada por ativação neurohormonal, fatores locais, inflamação, isquemia, necrose e apoptose celular. Os miócitos são as principais células envolvidas na RC. Avaliamos o papel da hiperfosfatemia e do paratormônio (PTH) em animais urêmicos. Trinta e dois ratos Wistar machos foram submetidos à paratireoidectomia (PTX) e nefrectomia (Nx), com reposição contínua de PTH em concentração fisiológica (PTHf= 0,022 ug/100g/h) ou elevada (PTHe=0,11 ug/100g/h). Os animais sham (N=16) foram operados e recebiam infusão de veículo. Apenas o conteúdo de fósforo nas dietas era diferente, ou seja: pobre=0,2% (pP) ou rica em fósforo=1,2% (rP). Dividimos os animais em 6 grupos: Sham: Sham-pP (G1), Sham-rP (G2); PTX+Nx: PTHf-pP (G3), PTHf-rP (G4), PTHe-pP (G5), PTHe-rP (G6). Semanalmente determinamos o peso e a pressão arterial caudal. Creatinina, fósforo, cálcio PTH e hematócrito foram analisados. Após 8 semanas os animais foram sacrificados. A hipertrofia e fibrose miocárdicas foram analisadas com o sistema digital Leica. O peso do coração corrigido por 100g peso corporal foi maior nos grupos G5 e G6 e apresentou uma correlação positiva com hipertrofia e fibrose miocárdica. A hipertrofia e fibrose foram menores no G3, quando comparado aos grupos Nx. A hipertrofia miocárdica foi maior no G6, evidenciando o papel do P neste processo. A fibrose mocárdica ocorreu principalmente em subendocárdio e foi mais intensa no G6. Analisamos a expressão do fator transformador de crescimento (TGF-beta) e angiotensina II que foram mais intensas nos grupos G5 e G6. As lesões das artérias coronarianas foram avaliadas de forma semi-quantitativa e os animais G5 e G6 mostraram calcificações de camada média. A expressão da alfa-actina se correlacionou negativamente com as lesões coronarianas. Nossos resultados demonstraram a importância do fósforo e PTH na fisiopatologia da DCV, sendo necessário um melhor controle destes elementos para prevenção de mortalidade nos pacientes com DRC. / Cardiovascular disease (CVD) is the leading cause of mortality in patients with chronic kidney disease (CKD), and left ventricular hypertrophy (LVH) is the most common alteration. Pathologic cardiac remodeling (CR) occurs in response to injuries such as volume or pressure overload, and it is influenced by neurohormonal activation, local factors, inflammation, ischemia, necrosis and cellular apoptosis. Myocytes are the principal cells involved in CR. We evaluated the role of hyperphosphatemia and parathyroid hormone (PTH) in uremic animals. Thirty-two male Wistar rats were submitted to parathyroidectomy (PTX) and nephrectomy (Nx), with PTH continuous replacement in physiologic concentration (PTHf=0.022ug/100g/h) or elevated (PTHe=0.11ug/100g/h). The sham animals (N=16) were operated and received vehicle infusion. Only the phosphorus content in diets was different, that is: poor = 0.2% (pP) or rich in phosphorus = 1.2% (rP). We divided the animals into 6 groups: Sham: Sham-pP (G1), Sham-rP (G2); PTX+Nx: PTHf-pP (G3), PTHf-rP (G4), PTHe-pP (G5), PTHe-rP (G6). We determined the weight and caudal blood pressure weekly. Creatinine, phosphorus, PTH calcium and hematocrit were analyzed. After 8 weeks, the animals were sacrificed. Myocardial hypertrophy and fibrosis were analyzed using Leica digital system. The weight of the heart corrected for 100g body weight was greater in groups G5 and G6 and presented a positive correlation with myocardial hypertrophy and fibrosis. Hypertrophy and fibrosis were lower in G3, when compared to Nx groups. Myocardial hypertrophy was higher in G6, determining the role of P in this process. Myocardial fibrosis occurred mainly in subendocardium and was more intense in G6. We analyzed the expression of transforming growth factor (TGF-alfa) and angiotensin II, which were more intense in groups G5 and G6. Coronary artery lesions were evaluated semiquantitatively and G5 and G6 animals showed middle layer calcifications. Expression of alfa-actin correlated negatively with coronary lesions. Our results demonstrated the importance of phosphorus and PTH in the pathophysiology of CVD; therefore, a better control of these elements is required in order to prevent mortality in patients with CKD.